ClonoSEQ assay for the detection of lymphoid malignancies

References

• van der Velden VH, Cazzaniga G, Schrauder A, et al. European study group on MRD detection in ALL (ESG-MRD-ALL). Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–611.
   PubMed Web of Science ®Google Scholar
• Kotrova M, Trka J, Kneba M, et al. Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia? Mol Diagn Ther. 2017;21:481–492.
   PubMed Web of Science ®Google Scholar
• Nunes V, Cazzaniga G, Biondi A. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Expert Rev Mol Diagn. 2017;17:953–963.
   PubMed Web of Science ®Google Scholar
• Dogliotti I, Drandi D, Genuardi E, et al. New molecular technologies for minimal residual disease evaluation in B-cell lymphoid malignancies. J Clin Med. 2018 Sep;18(7):9.
   Google Scholar
• Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol. 2019;94:257–265.
   PubMed Web of Science ®Google Scholar
• Jung D, Giallourakis C, Mostoslavsky R, et al. Mechanisms and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541–570.
   PubMed Web of Science ®Google Scholar
• Schatz DG, Swanson PC. V(D)J recombination mechanisms of initiation. Annu Rev Genet. 2011;45:167–202.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Langerak AW, Groenen PJ, Brüggemann M, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–2171.
   PubMed Web of Science ®Google Scholar
• Boone E, Heezen KC, Groenen PJTA, et al., EuroClonality Consortium. PCR GeneScan and heteroduplex analysis of rearranged immunoglobulin or T-cell receptor genes for clonality diagnostics in suspect lymphoproliferations. Methods Mol Biol. 2019;1956:77–103.
   PubMedGoogle Scholar
• Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from children’s oncology group study AALL0232. Blood. 2015;126:964–971.
   PubMed Web of Science ®Google Scholar
• Langerak AW, Brüggemann M, Davi F, et al. High-Throughput Immunogenetics for clinical and research applications in immunohematology: potential and challenges. J Immunol. 2017;198:3765–3774.
   PubMed Web of Science ®Google Scholar
• Arcila ME, Yu W, Syed M, et al. Establishment of Immunoglobulin Heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms. J Mol Diagn. 2019;21:330–342.
   PubMed Web of Science ®Google Scholar
• Carlson CS, Emerson RO, Sherwood AM, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Comm. 2013;4:2680.
   PubMed Web of Science ®Google Scholar
• Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120:5173–5180.
   PubMed Web of Science ®Google Scholar
• Gawad C, Pepin F, Carlton VE, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012;120:4407–4417.
   PubMed Web of Science ®Google Scholar
• Bashford-Rogers RJM, Nicolau KA, Bartram J, et al. Eye on the B-ALL: B-cell recptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. Leukemia. 2016;30:2312–2321.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–3214.
   PubMed Web of Science ®Google Scholar
• Inaba H, Azzato EM, Mullighan CG. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: the St. Jude children’s research hospital approach. Front Pediatr. 2017 Dec;4(5):258.
   Google Scholar
• Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20:4540–4548.
   PubMed Web of Science ®Google Scholar
• Sala Torra O, Othus M, Williamson DW, et al. Next-generation sequencing in adult B cell acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2017;23:691–696.
   PubMed Web of Science ®Google Scholar
• Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131:1350–1359.
   PubMed Web of Science ®Google Scholar
• Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20:1307–1313.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Carlson C, Langholz B, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125:3501–3508.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual diease detection in multiple myeloma. Blood. 2014;123:3073–3079.
   PubMed Web of Science ®Google Scholar
• Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65. (DFCI Study 10-106), NCT01208662.
   Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 Feb 8;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study. Leukemia. 2016;30:929–936.
   PubMed Web of Science ®Google Scholar
• Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013 Aug;27(8):1659–1665.
   PubMed Web of Science ®Google Scholar
• Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–2908.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132:2016–2025.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Pittaluga S, et al. Comparative study of circulating tumor DNA and computerized tomography monitoring in untreated diffuse large B-cell lymphoma. Lancet Oncol. 2015;16:541–549.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Davids MS, Jacobson C, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013;163:123–126.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679–3687.
   PubMed Web of Science ®Google Scholar
• Yousfi Monod M, Giudicelli V, Chaume D, et al. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics. 2004 Aug 4;20(Suppl 1):i379–85.
   PubMedGoogle Scholar
• Lefranc MP, Giudicelli V, Duroux P, et al. IMGT®, the international ImMunoGeneTics information system® 25 years on. Nucleic Acids Res. 2015 Jan;43(Database issue):D413–22.
   PubMed Web of Science ®Google Scholar
• Bystry V, Reigl T, Krejci A, et al. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics. 2017;33:435–437.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Sanchez-Vega B, Barrio S, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma. Leukemia. 2017;31:1446–1449.
   PubMed Web of Science ®Google Scholar
• Soto C, Bombardi RG, Branchizio A, et al. High frequency of shared clonotypes in human B cell repertoires. Nature. 2019;566:398–402.
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang J, Wang J, et al. Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet. 2019;51:560–567.
   PubMed Web of Science ®Google Scholar